Neuromuscular Disorders

Featured Article

Primary Periodic Paralysis: Advice for Clinicians & Future Directions

Primary Periodic Paralysis: Advice for Clinicians & Future Directions

Neurology Advisor speaks with Annabelle Baughan, a retired hematologist-oncologist, and discusses her personal experience with Andersen-Tawil syndrome.

Latest

Eculizumab May Improve Independent Walking Ability in Guillain-Barré Syndrome

Eculizumab May Improve Independent Walking Ability in Guillain-Barré Syndrome

High-dose intravenous immunoglobulin therapy was administered to all patients and may have contributed to neutralization of eculizumab.

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Facioscapulohumeral Muscular Dystrophy Treatment Gets Fast Track Status

Facioscapulohumeral Muscular Dystrophy Treatment Gets Fast Track Status

ACE-083 is currently being studied in a Phase 2 trial for FSHD and another for Charcot-Marie-Tooth (CMT) disease.

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.

Belimumab Nonsuperior to Placebo for Reducing Symptoms of Myasthenia Gravis

Belimumab Nonsuperior to Placebo for Reducing Symptoms of Myasthenia Gravis

The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.

Alemtuzumab Associated With Acute Acalculous Cholecystitis, Ischemia in Relapsing-Remitting MS

Alemtuzumab Associated With Acute Acalculous Cholecystitis, Ischemia in Relapsing-Remitting MS

Cases of acalculous cholecystitis and a single case of acute coronary syndrome associated with the use of alemtuzumab are reported.

Primary Periodic Paralysis: Advice for Clinicians & Future Directions

Primary Periodic Paralysis: Advice for Clinicians & Future Directions

Neurology Advisor speaks with Annabelle Baughan, a retired hematologist-oncologist, and discusses her personal experience with Andersen-Tawil syndrome.

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.

Sign Up for Free e-newsletters

CME Focus